causal

Small Rare Disease Markets Go Unserved Economically

Many small genetic disease markets with known mechanisms go unserved because a drug earning a few tens of millions a year cannot justify the $100 to $300 million development cost, so reducing trial costs would unlock valuable drugs.

causalpending

Speaker

Alex

Evidence Quote

“there's a lot of, I think, alpha that could be unlocked in making the process much cheaper in how drugs are tested and validated”

Source

Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]— Invest Like the Best
Created: 11/14/2026, 6:42:06 AM

Your notes

Loading notes...